Article
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
European urology - 1 Dec 2020
Herberts Cameron, Murtha Andrew J, Fu Simon, Wang Gang, Schönlau Elena, Xue Hui, Lin Dong, Gleave Anna, Yip Steven, Angeles Arkhjamil, Hotte Sebastien, Tran Ben, North Scott, Taavitsainen Sinja, Beja Kevin, Vandekerkhove Gillian, Ritch Elie, Warner Evan, Saad Fred, Iqbal Nayyer, Nykter Matti, Gleave Martin E, Wang Yuzhuo, Annala Matti, Chi Kim N, Wyatt Alexander W
Abstract excerpt
BACKGROUND: Activating mutations in AKT1 and PIK3CA are undercharacterised in metastatic castration-resistant prostate cancer (mCRPC), but are linked to activation of phosphatidylinositol 3-kinase (PI3K) signalling and sensitivity to pathway inhibitors in other cancers. OBJECTIVE: To determine the prevalence, genomic context, and clinical associations of AKT1/PIK3CA activating mutations in mCRPC. DESIGN, SETTING,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.